Gonadotropin-Releasing Hormone Agonists and the Risks of Type 2 Diabetes and Cardiovascular Disease in Men with Prostate Cancer

Author： Saylor Philip J.  

Publisher： Adis International

ISSN： 0012-6667

Source： Drugs, Vol.71, Iss.3, 2011-02, pp. : 255-261

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Gonadotropin-releasing hormone agonists in breast cancer

By  

Inpharma, Vol. 1, Iss. 1589, 2007-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Emerging gonadotropin-releasing hormone agonists

By Beyer Daniel Alexander   Amari Feriel   Thill Marc   Schultze-Mosgau Askan   Al-Hasani Safaa   Diedrich Klaus   Griesinger Georg  

Expert Opinion on Emerging Drugs, Vol. 16, Iss. 2, 2011-06 ,pp. : 323-340

Informa Healthcare

Access to resources Recommend Favorite

Agonists of luteinizing hormone-releasing hormone in prostate cancer

By Rick Ferenc G   Block Norman L   Schally Andrew V  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 16, 2013-11 ,pp. : 2237-2247

Informa Healthcare

Access to resources Recommend Favorite

The Estrogen Myth: Potential Use of Gonadotropin-Releasing Hormone Agonists for the Treatment of Alzheimer's Disease

By Casadesus Gemma  

Drugs in R&D, Vol. 7, Iss. 3, 2006-01 ,pp. : 187-193

Adis International

Access to resources Recommend Favorite

New developments in the use of peptide gonadotropin-releasing hormone antagonists versus agonists

By Schultze-Mosgau Askan   Griesinger Georg   Altgassen Christopher   von Otte Soeren   Hornung Daniela   Diedrich Klaus  

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 9, 2005-09 ,pp. : 1085-1097

Informa Healthcare

Access to resources Recommend Favorite